Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers

Exclusion Criteria

• •Clinically significant illness or surgery within 8 weeks prior to dosing.
• •Positive for hepatitis B, hepatitis C, or HIV at screening as per medical history.
• •History of allergic reactions to the study drug and/or its excipients.
• •Subjects concurrently treated with drugs that are metabolized through CYP3A4, including but not limited to pimozide, terfenadine, astemizole, or cisapride, ketoconazole, itraconazole, clarithromycin, diltiazem, warfarin, rifampin, carbamazepine, and phenytoin etc.
• •History of drug or alcohol abuse within the last 6 months.
• •Severe mental disorders.
• •Blood donation of 50 mL to 499 mL of whole blood within 30 days, or more than 499 mL of whole blood within 56 days prior to drug administration.
• •Pregnant or breastfeeding.
• •Use of recreational drugs, prescription medications (other than hormonal contraceptive agents),non-prescription medications (over-the-counter) or natural health products within 7 days or 5 half-lives (whichever is longer) prior to the administration of the first dose of study medication.
• •Consumed grapefruit or grapefruit products within 7 days of each study period
• •Any reason which, in the opinion of the investigator, would prevent the subject from participating in the study.